MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
Optasia Medical, Sudbury, Mass.
Optasia Medical makes a trio of software products to analyze joint imaging data for the spine, hand and knee.
Officers
Peter Steiger, CEO
Alan Brett, CTO
Directors
Peter Steiger, Alan Brett, Ranjeet Bhatia, Louis Nisbet, Jean Chaintreuil
Investors
Saffron Hill Ventures, Beringea, Foresight Group
Products
SpineAnalyzer – Vertebral Fracture Assessment for Osteoporosis, ready for commercialization (CE-marked, FDA approval pending). Beta testing has been initiated at leading institutions in the U.S. and EU. SpineAnalyzer may revolutionize the way physicians manage patients because of recently revised guidelines for the management of osteoporosis. Market size $272 million.
HandAnalyzer – Joint Damage Assessment for Rheumatoid Arthritis, demonstration prototype ready, product launch expected in Q1/2010. HandAnalyzer is a workflow tool for scoring hand and foot x-rays to document joint damage caused by rheumatoid arthritis. Because RA drugs can have significant side effects and cost $10k-$20k per year, the ability to individually and quantitatively assess joint damage and disease progression plays an important role in managing treatment. Market Size $91 million.
KneeAnalyzer – Joint Damage Assessment for Osteoarthritis, already generating revenue through Imaging Core
Labs (ICLs) since 2007, the emerging standard for the characterization of knee joint space pathology in clinical trials of disease-modifying OA drugs with a growing body of literature demonstrating its performance. Market Size $447 million.